EFFICACY AND SAFETY OF COMBINATION TREATMENT WITH ABATACEPT AND METHOTREXATE AND MONOTHERAPY WITH METHOTREXATE IN PATIENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

V A Kel'Tsev,N S Pryanichkova,S А Gorunov,L I Grebenkina,N V Lagoda

doi:10.15690/vsp.v11i6.500

Abstract

The results of efficacy and safety study of abatacept and methotrexate combination therapy (n=12) in comparison with methotrexate monotherapy (n =41) in patients with polyarticular juvenile idiopathic arthritis at the age of 4–17 years old are shown in this article. The duration of the observation was 1 year. Abatacept was introduced at a dose of 10 mg/kg at 1 st , 2d and then — every 4 th week. In 48 weeks clinical remission and decrease of laboratory markers of activity was registered in 35% of patients treated with abatacept and methotrexate and in 16% of patients treated only with methotrexate.

Highlights

Efficacy and safety of combination treatment with abatacept and methotrexate and monotherapy with methotrexate in patients with polyarticular juvenile idiopathic arthritis
The results of efficacy and safety study of abatacept and methotrexate combination therapy (n = 12) in comparison with methotrexate monotherapy (n = 41) in patients with polyarticular juvenile idiopathic arthritis at the age of 4–17 years old are shown in this article
Abatacept was introduced at a dose of 10 mg/kg at 1st, 2d and — every 4th week

Summary

Introduction

Efficacy and safety of combination treatment with abatacept and methotrexate and monotherapy with methotrexate in patients with polyarticular juvenile idiopathic arthritis. У детей, получавших метотрексат, значительное уменьшение числа суставов с нарушением функции отмечали с 12-й нед терапии (р < 0,01), тогда как у пациентов, получавших абатацепт с метотрексатом, восстановление функции в суставах было зафиксировано уже после 2-го введения абатацепта (через 4 нед) (р < 0,001). После 6-го введения абатацепта (20-я нед) медиана индекса СНАQ у всех детей, получавших комбинацию препаратов, снизилась до 0, тогда как у пациентов, лечившихся метотрексатом, она составила 0,6 балла (р < 0,05).

Results

Conclusion